ADD1: A Drug Target / Disease Biomarker (G118)

Target Name: ADD1

NCBI ID: G118

ADD1

ADD1: A Drug Target / Disease Biomarker

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder that affects millions of people worldwide. It is characterized by symptoms such as difficulty paying attention, impulsivity, and hyperactivity. Despite the availability of several medications that can treat ADHD, the condition remains a significant public health issue.

One potential drug target for ADHD is the neurotransmitter dopamine. Dopamine is a chemical that transmits signals in the brain related to motivation, pleasure, and reward. Imbalances in dopamine levels have been implicated in the symptoms of ADHD.

One class of drugs that target dopamine in the brain is called dopamine agonists. These drugs work by increasing the levels of dopamine in the brain. One such drug is called atomoxetine (also known as Adderall), which is a commonly prescribed medication for ADHD.

Atomoxetine works by increasing the levels of dopamine in the brain by blocking the action of a chemical called norepinephrine. Norepinephrine is a neurotransmitter that helps regulate the levels of dopamine in the brain. By blocking its action, atomoxetine increases the levels of dopamine available in the brain.

In addition to increasing dopamine levels, atomoxetine can also improve the levels of another neurotransmitter called dopamine receptor function. This means that the drug can increase the effectiveness of dopamine, making it more effective at treating ADHD symptoms.

Another potential drug target for ADHD is the neurotransmitter GABA. GABA is a chemical that transmits signals in the brain related to relaxation and inhibition. Imbalances in GABA levels have also been implicated in the symptoms of ADHD.

One class of drugs that target GABA in the brain is called GABA agonists. These drugs work by increasing the levels of GABA in the brain. One such drug is called benzodiazepines, which are commonly prescribed for anxiety and other conditions.

In addition to increasing GABA levels, benzodiazepines can also improve the levels of another neurotransmitter called GABA receptor function. This means that the drug can increase the effectiveness of GABA, making it more effective at treating ADHD symptoms.

Another potential drug target for ADHD is the neurotransmitter serotonin. Serotonin is a chemical that transmits signals in the brain related to mood, appetite, and sleep. Imbalances in serotonin levels have also been implicated in the symptoms of ADHD.

One class of drugs that target serotonin in the brain is called serotonin reuptake inhibitors. These drugs work by blocking the action of a chemical called serotonin reuptake, which is a neurotransmitter that transmits signals in the brain related to mood, appetite, and sleep.

In addition to blocking serotonin reuptake, serotonin reuptake inhibitors can also increase the levels of serotonin in the brain. This means that the drug can increase the effectiveness of serotonin, making it more effective at treating ADHD symptoms.

Another potential drug target for ADHD is the neurotransmitter dopamine. Dopamine is a chemical that transmits signals in the brain related to motivation, pleasure, and reward. Imbalances in dopamine levels have been implicated in the symptoms of ADHD.

One class of drugs that target dopamine in the brain is called dopamine agonists. These drugs work by increasing the levels of dopamine in the brain. One such drug is called atomoxetine (also known as Adderall), which is a commonly prescribed medication for ADHD.

Atomoxetine works by blocking the action of a chemical called norepinephrine, which is a neurotransmitter that helps regulate the levels of dopamine in the brain. By blocking its action, atomoxetine increases the levels of dopamine available in the brain.

Protein Name: Adducin 1

Functions: Membrane-cytoskeleton-associated protein that promotes the assembly of the spectrin-actin network. Binds to calmodulin

The "ADD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets